Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Returns
Return on assets-26.4%+56.1pp-23.8%+41.5pp-34.6%-8.5pp-80.7%+4.2pp-82.5%-29.9pp
Liquidity
Current ratio23.8×-6.3×22.4×-6.5×16.9×-6.0×27.4×+0.8×30×+30.0×
Quick ratio23.8×-6.3×22.4×-6.5×16.9×-6.0×27.4×+0.8×30×+30.0×
Cash ratio-4.2×3.1×-1.7×4.4×+2.2×5.4×-6.5×7.1×-10.4×
Leverage
Debt-to-equity
Debt-to-assets0.0×0.0×0.0×0.0×-48.0×
Valuation
Market capitalization$2.43B$1.47B$930.43M
Enterprise value$2.38B$1.42B$841.09M
Price / book3.1×1.9×
Free cash flow yield-3.8%
Earnings yield-4.8%-7.2%-17.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Oruka Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Oruka Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.